Clinical Trial: Individual Following in Anal Cancer With PET/CT

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: Individual Following in Anal Cancer With PET/CT

Brief Summary:

Anal canal cancer is a relatively rare disease, representing 1.2% of digestive cancers and 6% of anorectal cancers. Incidence is less than 1/100 000 of the general population. However, the incidence has increased considerably over the past three decades. The main risk factors are HPV infections and smoking. Initial treatment comprises radiochemotherapy or radiotherapy alone, according to the patient's tumor stage and tolerance of chemotherapy. The choice of the most appropriate treatment strategy will condition the patient's prognosis. Consequently, early assessment of the initial extension of the tumor, its therapeutic response and relapses constitute determining factors in the management of the disease Despite the good results obtained, persistent disease is observed in 30% of cases and abdominal-pelvic salvage amputation can then prove effective in cases of local or loco-regional relapse. The great majority of relapses occur within 2 years after treatment. Reported prognostic survival factors are the T stage, size inferior or superior to 4 cm and inguinal or pelvic lymph node involvement.

The rules for follow-up are not substantiated by high levels of proof. Follow-up focuses principally on the clinical examination although the type and frequency of the paraclinical examinations are not backed by any consensus.


Detailed Summary: Post-treatment 18-FDG PET scan at 2 months can prove useful to predict locoregional or metastatic recurrence in patients treated by radiochemotherapy or radiotherapy in the anal canal cancer setting. There appear to be an FDG intensity variable and a metabolic response criterion enabling establishment of two groups of patients: low recurrence risk versus high recurrence risk at 2 years.
Sponsor: Centre Antoine Lacassagne

Current Primary Outcome: time of disease-free survival [ Time Frame: 3 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • best metabolic response measurement variable: SUVmax [ Time Frame: 3 years ]
  • best metabolic response measurement variable: SUVmean [ Time Frame: 3 years ]
  • best metabolic response measurement variable: SUL peak [ Time Frame: 3 years ]
  • best metabolic response measurement variable: Metabolic Total Volume (MTV) [ Time Frame: 3 years ]
  • best metabolic response measurement variable: Total Lesion Glycolysis (TLG) [ Time Frame: 3 years ]
  • best treatment response criterion: SUV or metabolic volume threshold [ Time Frame: 3 years ]
  • best treatment response criterion: ratio (SUV or metabolic volume) [ Time Frame: 3 years ]
  • best treatment response criterion: complete or partial metabolic response according to EORTC or PERCIST criteria [ Time Frame: 3 years ]


Original Secondary Outcome: Same as current

Information By: Centre Antoine Lacassagne

Dates:
Date Received: February 22, 2016
Date Started: November 2014
Date Completion: June 2018
Last Updated: April 2, 2017
Last Verified: April 2017